Table 8. Outcomes of heparin induced thrombocytopenia in patients on ECMO.

Variable	VA-ECMO (n=15)	VV-ECMO (n=13)	Total (n=28)	P value
Hospital stay (days), median [IQR]	51 [35–61]	35 [23–79]	42 [28–70]	0.855
Follow up from admission (days), median [IQR]	86 [60–211]	35 [23–79]	60 [39–123]	0.143
Follow up from ECLS (days), median [IQR]	172 [96–253]	54 [24–92]	96 [44–156]	0.149
Follow up from platelet nadir (days), median [IQR]	168 [138–197]	39 [10–78]	88 [25–111]	0.165
Overall survival, n (%)	8 (53.3)	8 (61.5)	16 (57.1)	0.956
Heart transplant, n (%)	1 (6.7)	0 (0.0)	1 (3.6)	1.000
Lung transplant, n (%)	0 (0.0)	2 (15.4)	2 (7.1)	0.400
Causes of death, n (%)
Multiorgan failure	0 (0.0)	2 (15.4)	2 (7.1)	0.400
Ischemic colitis	0 (0.0)	1 (7.7)	1 (3.6)	0.942
Sepsis	1 (6.7)	0 (0.0)	1 (3.6)	1.000
ARDS	0 (0.0)	1 (7.7)	1 (3.6)	0.942
H1N1 influenza	0 (0.0)	1 (7.7)	1 (3.6)	0.942
Pulmonary contusion	0 (0.0)	1 (7.7)	1 (3.6)	0.942
Unspecified	6 (40.0)	0 (0.0)	6 (21.4)	0.035

VA, veno-arterial; VV, veno-venous; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; ECLS, extracorporeal life support; ARDS, acute respiratory distress syndrome.